Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;54(6):600-605.
doi: 10.1111/hepr.14011. Epub 2024 Jan 17.

Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease

Keito Suzuki  1 , Nobuharu Tamaki  1 , Masayuki Kurosaki  1 , Yuka Takahashi  1 , Yudai Yamazaki  1 , Naoki Uchihara  1 , Yuki Tanaka  1 , Haruka Miyamoto  1 , Michiko Yamada  1 , Taisei Keitoku  1 , Risa Okada  1 , Mayu Higuchi  1 , Kenta Takaura  1 , Shohei Tanaka  1 , Chiaki Maeyashiki  1 , Yutaka Yasui  1 , Kaoru Tsuchiya  1 , Hiroyuki Nakanishi  1 , Namiki Izumi  1
Affiliations

Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease

Keito Suzuki et al. Hepatol Res. 2024 Jun.

Abstract

Aim: A multisociety consensus group proposed a new nomenclature for metabolic dysfunction-associated steatotic liver disease (MASLD). Although patients with nonalcoholic fatty liver disease (NAFLD) are expected to be reclassified as patients with MASLD under the new nomenclature, the concordance between MASLD and NAFLD remains unclear. Moreover, waist circumference could be adjusted by ethnicity for diagnosing MASLD; however, there are limited data on the optimal waist circumference in the Japanese population.

Methods: This cross-sectional study was conducted on 3709 Japanese patients with NAFLD. The primary endpoint was the prevalence of MASLD in patients with NAFLD. The difference between the original waist circumference criteria (>94 cm for men and >80 cm for women) and the Japanese metabolic syndrome criteria (≥85 cm for men and ≥90 cm for women) for concordance between NAFLD and MASLD was also investigated.

Results: According to the original criteria, the prevalence of MASLD in patients with NAFLD was 96.7%. Similarly, according to the Japanese waist circumference criteria, 96.2% of patients with NAFLD could be reclassified as those with MASLD. The concordance rate was significantly higher in the original criteria than in the Japanese criteria (p = 0.02).

Conclusions: NAFLD could be considered MASLD using the original MASLD criteria in the Japanese population, and insights from NAFLD research could be applied to MASLD.

Keywords: concordance; metabolic dysfunction‐associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); steatotic liver disease (SLD); waist circumference.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. https://doi.org/10.1038/nrgastro.2017.109
    1. Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, Tobita H, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: a large‐scale multicenter retrospective study. Hepatol Res. 2023;53(11):1059–1072. https://doi.org/10.1111/hepr.13947
    1. Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta‐analysis with individual and forecasting analysis, 1995‐2040. Hepatol Int. 2021;15(2):366–379. https://doi.org/10.1007/s12072‐021‐10143‐4
    1. Huang DQ, El‐Serag HB, Loomba R. Global epidemiology of NAFLD‐related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223–238. https://doi.org/10.1038/s41575‐020‐00381‐6
    1. Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, et al. Clinical outcomes in biopsy‐proven nonalcoholic fatty liver disease patients: a multicenter registry‐based cohort study. Clin Gastroenterol Hepatol. 2023;21(2):370–379. https://doi.org/10.1016/j.cgh.2022.01.002

LinkOut - more resources